Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer

John R. Eckardt(GlaxoSmithKline (Italy)), Graham Ross(National Cancer Centre Japan), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), Jean-Louis Pujol(GlaxoSmithKline (Italy)), Andrea Ardizzoni(Azienda Ospedaliero-Universitaria Careggi), Élisabeth Quoix(Université de Strasbourg), Zsolt Pápai(GlaxoSmithKline (Italy)), R. Poulin(GlaxoSmithKline (Italy)), A. Preston(GlaxoSmithKline (Italy)), G. Dane(GlaxoSmithKline (Italy))
Journal of Clinical Oncology
May 19, 2007
10.1200/jco.2006.08.3998
Cited by 384

Related Papers

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
|The Lancet|2005|2.1k
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
|Journal of Clinical Oncology|2004|1.7k